Loading...
XNAS
MDWD
Market cap159mUSD
Oct 08, Last price  
12.42USD
1D
-3.35%
1Q
-13.09%
Jan 2017
-61.25%
IPO
-90.23%
Name

Mediwound Ltd

Chart & performance

D1W1MN
XNAS:MDWD chart
P/E
—
P/S
9.41
EPS
—
Div yield, %
—
Shrs. gr., 5y
23.96%
Rev. gr., 5y
-4.87%
Revenues
17m
-16.14%
000259,000601,0001,558,0002,496,0003,401,00031,789,00021,763,00023,763,00026,496,00018,686,00020,222,00016,959,000
Net income
-24m
L-20.99%
-6,169,00010,940,000-15,351,000-18,875,000-22,088,000-18,885,000-22,149,000-1,057,0004,955,000-9,196,000-13,551,000-19,599,000-6,716,000-30,224,000-23,879,000
CFO
-15m
L+6.65%
-2,960,000-4,728,000-9,740,000-16,493,000-19,601,000-16,445,000-16,455,000-12,154,0008,289,000-6,895,000-8,916,000-11,885,000-10,465,000-13,624,000-14,530,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Key people

Sharon Malka
Chief Executive Officer · since 2019
Lior Rosenberg
Chief Medical Technology Officer · since 2001
Yaron Meyer
General Counsel and Corporate Secretary · since 2013
Carsten Henke
Chief Commercial Officer EU · since 2014
Samuel J. Moed
Director · since 2020
Assaf Segal
Director · since 2017
Vickie R. Driver
Independent Director · since 2017
Nissim Mashiach
Independent Director · since 2017
URL
https://www.mediwound.com/
IPO date
Mar 20, 2014
Employees
83
Domiciled in
IL
Incorporated in
IL
Headquarters & legal address
42 HAYARKON STREET
YAVNE, M 81227
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT